AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Tumor model established in HLA-A*0201 transgenic mice to test vaccines.
2003 JAN 1 - (NewsRx.com & NewsRx.net) -- According to recent research from the United States, "With the increasing generation of new cancer vaccine strategies, there is also an increasing demand for preclinical models that can carefully predict the efficacy of these vaccines in humans. However, the only tumor models available to study vaccines against human papillomavirus (HPV) 16 have been developed in C57BL/6 mice. To test the HLA-restricted capabilities of vaccination strategies, it is important to establish a tumor model in HLA-A*0201 transgenic mice."
G.L. Eiben and colleagues, Loyola University Chicago, reported that "[b]y transfecting heart lung fibroblasts from HLA-A*0201 mice with HPV16 E6 and E7 oncogenes and H-Ras V12, we have generated a transgenic cell line that is tumorigenic in HLA-A*0201 mice."
"The dominant H-2D(b) HPV16 E7 epitope was removed from the E7 construct to ensure that all antitumor responses were mediated through the HLA-A*0201-restricted epitopes. We used this tumor model to test the efficacy of two genetic vaccines: a plasmid DNA multi-epitope vaccine encoding human epitopes of HPV16, and a Venezuelan equine encephalitis (VEE) virus-based vector to deliver HPV16 E6 and E7 RNA."
Eiben's group demonstrated that both the "multi-epitope DNA- and VEE-based vaccines protect ...
- EntreMed's Panzem(R) Demonstrates Antitumor Activity in Brain Tumor Model.
- Press release article from: PR Newswire December 21, 2006 700+ words
...2ME2 or 2-methoxyestradiol), in an orthotopic brain tumor model. The results of the studies, conducted by EntreMed collaborators...histological evaluation in a preclinical orthotopic glioma tumor model, 2ME2 treatment resulted in a dose-dependent reduction...
- Escape of mammary cell senescence can be seen in murine mammary tumor model.
- Newspaper article from: Biotech Week June 9, 2004 700+ words
...Researchers discuss gene alterations observed in the murine mammary tumor model. "Human mammary epithelial cells emerge spontaneously from...scientists in the United States report. "In a mouse mammary tumor model, the spontaneous escape of senescence can be observed as...
- AVAX Technologies Announces Publication of Paper on the Anti-Metastatic...
- Press release article from: PR Newswire June 11, 2002 700+ words
...hapten-modified autologous tumor cell vaccine in an animal tumor model" in the journal Cancer Immunology Immunotherapy (2002...after removal of primary tumors in a mouse metastatic mammary tumor model compared to that of untreated animals. Furthermore, the...
- Tumor model traces deadly progression of cells.
- Newspaper article from: Genomics & Genetics Weekly March 28, 2003 700+ words
...scene at different stages of the disease, treatments can be tailored to the patient's stage of cancer progression. The tumor model constructed by Singh and his colleagues also should enable earlier diagnosis of oral cancer, which currently depend on the...
- Tumor model traces deadly progression of cells.(oral cancer model)
- Newspaper article from: Cancer Weekly March 25, 2003 700+ words
...scene at different stages of the disease, treatments can be tailored to the patient's stage of cancer progression. The tumor model constructed by Singh and his colleagues also should enable earlier diagnosis of oral cancer, which currently depend on the...
- Researchers study a chemotherapy-resistant neural crest tumor model.
- Newspaper article from: Biotech Week June 9, 2004 700+ words
2004 JUN 9 - (NewsRx.com & NewsRx.net) -- In a neural crest tumor model, researchers are developing promising ways of combating chemotherapy resistance. According to recent research from the United...
- Positive CoFactor results reported in pancreatic tumor model.
- Newspaper article from: Biotech Business Week July 26, 2004 700+ words
...announced statistically significant tumor inhibition and survival using CoFactor combination treatments in a pancreatic tumor model. Results were presented by Mark J. Cantwell, director of Preclinical Programs for Adventrx, on June 26 at the Pancreatic...
- ADVENTRX Pharmaceuticals Presents Positive CoFactor(TM) Results in Pancreatic...
- Press release article from: PR Newswire June 28, 2004 700+ words
...announced statistically significant tumor inhibition and survival using CoFactor(TM) combination treatments in a pancreatic tumor model. Results were presented by Dr. Mark J. Cantwell, Director of Preclinical Programs for ADVENTRX, on Saturday, June 26...
Source: HighBeam Research, Tumor model established in HLA-A*0201 transgenic mice to test...